![](/images/graphics-bg.png)
Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review
المؤلفون المشاركون
Rutherford, George
Balayan, Tatevik
Horvath, Hacsi
المصدر
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-09-26
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Background.
Darunavir is a second-generation protease-inhibitor used with ritonavir (DRV/r) and two nucleoside reverse-transcriptase inhibitors as an option in first-line antiretroviral treatment (ART).
Methods.
We systematically reviewed randomized controlled trials (RCTs) of DRV/r versus other regimens in patients initiating ART.
We searched five bibliographic databases and other key resources.
We had no language limitations.
We assessed bias risk with the Cochrane tool and used GRADE to assess evidence quality.
We report findings in terms of risk ratio (RR) with 95% confidence intervals (CI).
Findings.
Three RCTs met inclusion criteria.
In plasma viral load suppression, DRV/r outperformed ritonavir-boosted lopinavir at 48 weeks (RR 1.13, 95% CI 1.03–1.25), 96 weeks (RR 1.11, 95% CI 1.02–1.21), and 192 weeks (RR 1.20, 95% CI 1.07–1.35).
DRV/r was similar to dolutegravir at 48 weeks (RR 0.96, 95% CI 0.87–1.06) but less effective at 96 weeks (RR 0.84, 95% CI 0.75–0.93).
At 96 weeks, DRV/r underperformed raltegravir (RR 0.94, 95% CI 0.88–0.99) but was similar to ritonavir-boosted atazanavir (RR 1.02, 95% CI 0.96–1.09).
Overall bias risk was moderate.
Evidence quality was also moderate.
Interpretation.
Initial ART regimens using DRV/r should be considered in future World Health Organization guidelines.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Balayan, Tatevik& Horvath, Hacsi& Rutherford, George. 2017. Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review. AIDS Research and Treatment،Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1130915
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Balayan, Tatevik…[et al.]. Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review. AIDS Research and Treatment No. 2017 (2017), pp.1-9.
https://search.emarefa.net/detail/BIM-1130915
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Balayan, Tatevik& Horvath, Hacsi& Rutherford, George. Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review. AIDS Research and Treatment. 2017. Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1130915
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1130915
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)